Last reviewed · How we verify
Norepinephrine-P
At a glance
| Generic name | Norepinephrine-P |
|---|---|
| Also known as | vasopressor |
| Sponsor | Dalian Municipal Central Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Caveolin-1 and Vascular Dysfunction (PHASE1)
- Locus-coeruleus Function in Normal Elderly and AD Risk (NA)
- EIT-guided PEEP Titration Versus Standard Ventilation in Bariatric Surgery (NA)
- COMPARISON BETWEEN EFFICACY OF NOREPINEPHRINE AND PHENYLEPHRINE BOLUSES for PREVENTION OF SPINAL ANAESTHESIA INDUCED HYPOTENSION IN OBSTETRICAL PATIENTS UNDERGOING EMERGENCY CESAREAN SECTION-A Double Blind Randomized Controlled Trial (NA)
- A Prospective Study of Vasopressor on Cerebral Oxygenation During General Anesthesia (PHASE4)
- Comparison Between Oxycodone and Pregabalin as Preemptive Analgesia (PHASE2, PHASE3)
- Vascular Dysfunction in Diabetes: Genes and Hormones
- Effect of Three Weight-adjusted Vasopressors for Elective Cesarean Delivery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Norepinephrine-P CI brief — competitive landscape report
- Norepinephrine-P updates RSS · CI watch RSS
- Dalian Municipal Central Hospital portfolio CI